Ibio (IBIO) AI Stock Analysis

• Market Cap: $12.02M
• Dividend Yield: N/A
• Average Volume (3M): 3.56M
• Price to Earnings (P/E): ―
• Beta (1Y): 0.68
• Revenue Growth: 650.00%
• EPS Growth: 89.72%
• Country: US
• Employees: 16
• Sector: Healthcare
• Sector Strength: 39
• Industry: Biotechnology
• EPS (TTM): -0.49
• Shares Outstanding: 16,219,280
• 10 Day Avg. Volume: 9,846,968
• 30 Day Avg. Volume: 3,563,197
• PEG Ratio: -0.12
• Price to Book (P/B): 70.92
• Price to Sales (P/S): 0.00
• P/FCF Ratio: -11.67
• Enterprise Value/Market Cap: 16.24
• Enterprise Value/Revenue: 169.69
• Enterprise Value/Gross Profit: 174.39
• Enterprise Value/Ebitda: -3.55
• 1Y Price Target: $5.00
• Price Target Upside: 575.68% Upside
• Rating Consensus: Moderate Buy
• Number of Analyst Covering: 1

• Rating: 42 Neutral
• Price Target: ―

IBIO's overall score is heavily impacted by significant financial challenges, including negative earnings and cash flow issues. The weak technical outlook and poor valuation metrics further weigh down the score. However, recent strategic corporate events provide some optimism for future growth, but they are not enough to offset the current financial difficulties.

Ibio Business Overview & Revenue Model

Company Description

iBio, Inc., a biotechnology company, provides contract development and manufacturing services to collaborators and third-party customers in the United States. The company operates in two segments: Biopharmaceuticals and Bioprocessing. Its lead therapeutic candidate is IBIO-100 that is being advanced for investigational new drug development for the treatment of systemic scleroderma and idiopathic pulmonary fibrosis. The company is also developing vaccine candidates comprising IBIO-200 and IBIO-201, which are in preclinical development for the prevention of severe acute respiratory syndrome coronavirus 2; and IBIO-400 for the treatment of classical swine fever. In addition, it is developing recombinant proteins for third parties on a catalog and custom basis; and offers a range of process development, manufacturing, filling and finishing, and bio analytic services. iBio, Inc. has a license agreement with Planet Biotechnology, Inc. to develop therapeutics for infectious diseases; collaboration agreement with The Texas A&M University System for the development of coronavirus disease 2019 vaccine candidates; license agreement with the University of Natural Resources and Life Sciences, Vienna; and collaboration agreement with CC-Pharming Ltd. The company is headquartered in Bryan, Texas.

How the Company Makes Money

iBio generates revenue through its biopharmaceutical development initiatives and contract manufacturing services. The company's primary revenue streams include licensing agreements, where it licenses its FastPharming technology to other organizations, and contract development and manufacturing services, where it produces plant-based biologics for clients. Additionally, iBio may engage in strategic partnerships and collaborations to enhance its development pipeline and expand its market reach. The company also seeks to advance its proprietary therapeutic candidates, which, upon successful development and commercialization, could provide additional revenue through sales or out-licensing deals.

Ibio Financial Statement Overview

Summary

Ibio's financial health is challenged by consistent losses and declining revenue, despite some improvement in leverage ratios. Cash flow issues persist, requiring external funding to maintain operations. The company faces significant risks due to its high operational inefficiencies and ongoing cash burn.

Income Statement

The company shows a declining trend in revenue, with significant losses in net income and EBIT. The TTM Gross Profit Margin is inflated due to the inclusion of other income streams, but the core revenue remains weak. The negative EBIT and EBITDA margins indicate operational inefficiency and high expenses relative to revenue.

Balance Sheet

The company's debt-to-equity ratio has improved, indicating better leverage management, but overall equity is decreasing. The equity ratio shows a decline in shareholders' equity as a proportion of total assets, suggesting potential risk. Despite these issues, the company has managed to reduce liabilities over time.

Cash Flow

Operating cash flow remains negative, reflecting ongoing cash burn, though financing activities have temporarily supported liquidity. The free cash flow to net income ratio is unfavorable, highlighting unsustainable operations without external financing.

Breakdown	TTM	Jun 2024	Jun 2023	Jun 2022	Jun 2021	Jun 2020
Income Statement
Total Revenue	375.00K	225.00K	0.00	1.88M	2.37M	1.64M
Gross Profit	1.12M	225.00K	-1.11M	2.17M	909.00K	935.00K
EBITDA	-15.11M	-14.02M	-28.12M	-25.72M	-18.34M	-11.74M
Net Income	-20.99M	-24.91M	-29.31M	-51.01M	-23.21M	-16.44M
Balance Sheet
Total Assets	19.10M	28.73M	41.21M	99.41M	146.97M	94.19M
Cash, Cash Equivalents and Short-Term Investments	4.96M	14.21M	4.30M	33.52M	96.97M	55.11M
Total Debt	2.93M	4.46M	17.07M	27.79M	32.72M	32.91M
Total Liabilities	7.72M	7.41M	25.83M	35.92M	38.40M	37.58M
Stockholders Equity	11.38M	21.32M	15.38M	63.48M	108.58M	56.62M
Cash Flow
Free Cash Flow	-15.77M	-18.76M	-36.17M	-49.11M	-35.23M	-14.50M
Operating Cash Flow	-15.54M	-18.55M	-30.44M	-37.48M	-30.06M	-13.35M
Investing Cash Flow	553.00K	906.00K	7.01M	-5.13M	-26.48M	-1.15M
Financing Cash Flow	13.74M	24.49M	2.30M	-6.13M	78.83M	65.19M

Ibio Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 0.74
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Negative
• RSI: Neutral
• STOCH: Positive

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For IBIO, the sentiment is Negative. The current price of 0.74 is below the 20-day moving average (MA) of 0.83, below the 50-day MA of 0.85, and below the 200-day MA of 2.44, indicating a bearish trend. The MACD of -0.07 indicates Negative momentum. The RSI at 40.39 is Neutral, neither overbought nor oversold. The STOCH value of 17.59 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for IBIO.

Ibio Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
ADXN	60 Neutral	$13.74M	0.81	-162.42%	―	-82.24%	―
Sector *	52 Neutral	$7.50B	0.31	-61.87%	2.27%	17.10%	1.59%
IBIO	42 Neutral	$12.02M	―	-90.83%	―	650.00%	89.72%
AFMDQ	42 Neutral	$536.01K	―		―	-95.23%	-325.89%
PSTV	39 Underperform	$15.12M	―	249.03%	―	-14.43%	16.04%
HOTH		$15.98M	―	-99.35%	―	―	―
RLYB	35 Underperform	$13.84M	―	-67.28%	―	―	27.35%

Ibio Corporate Events

iBio Enters Licensing Agreement for Obesity Treatment

On April 21, 2025, iBio, Inc. entered into an exclusive licensing agreement with AstralBio, Inc. for a first-in-class antibody targeting Activin E, aimed at treating obesity and cardiometabolic diseases. This agreement allows iBio to develop, manufacture, and commercialize the antibody, which has shown promising preclinical results in inducing fat-selective weight loss and improving cardiometabolic health. The licensing deal involves an upfront fee and potential milestone payments up to $28 million, with iBio taking full responsibility for the product’s development and commercialization. This strategic move is expected to expand iBio’s pipeline and strengthen its position in the cardiometabolic and obesity treatment market.

Spark’s Take on IBIO Stock

According to Spark, TipRanks’ AI Analyst, IBIO is a Underperform.

IBio faces significant financial challenges, with negative earnings and cash flow being major concerns. Technical analysis indicates weak momentum. While recent corporate events suggest potential for future growth, current financial and valuation issues heavily weigh down the stock, resulting in a low overall score.

To see Spark’s full report on IBIO stock, click here.

iBio Highlights Advancements in Obesity Antibody Programs

iBio, Inc. has updated its corporate presentation to highlight significant advancements in its antibody programs, particularly in obesity treatment. The updated data showcases the potential of IBIO-600, a long-acting anti-myostatin antibody, which demonstrated extended half-life and muscle growth in non-human primates, suggesting a long human half-life. Additionally, preclinical data on an Activin E antibody showed promising results in fat-selective weight loss and enhanced effects when combined with semaglutide, indicating a strong potential for addressing obesity and related metabolic conditions.

Spark’s Take on IBIO Stock

According to Spark, TipRanks’ AI Analyst, IBIO is a Neutral.

IBio’s stock score is primarily hindered by significant financial difficulties, including negative earnings and cash flow. Despite strong technical momentum, the negative valuation metrics and lack of profitability weigh heavily on the overall score. Recent corporate events indicate potential long-term growth, but they are not enough to offset the current financial and valuation concerns.

To see Spark’s full report on IBIO stock, click here.

iBio Reveals Promising Study Results for IBIO-600

On April 7, 2025, iBio announced promising data from a non-human primate study of its long-acting anti-myostatin antibody, IBIO-600, which showed potential for extended half-life and muscle growth. The study indicated that IBIO-600 could have a human half-life of up to 130 days, suggesting a reduced dosing schedule and positioning it as a best-in-class therapeutic for muscle preservation and weight loss. Additionally, preclinical data for a first-in-class Activin E antibody revealed significant fat-selective weight loss in obese mice, both as a monotherapy and in combination with semaglutide, highlighting its potential as a transformative obesity treatment.

Spark’s Take on IBIO Stock

According to Spark, TipRanks’ AI Analyst, (IBIO) is a Neutral.

IBio’s overall score reflects a mix of significant financial challenges, balanced by strong technical momentum. The company’s negative earnings and cash flow are major concerns, but recent strategic initiatives and positive technical indicators provide some optimism. Valuation remains a hurdle due to negative profitability metrics.

To see Spark’s full report on (IBIO) stock, click here.

iBio Announces Transfer to Nasdaq Capital Market

On February 19, 2025, iBio, Inc. announced its decision to transfer the listing of its common stock from NYSE American to the Nasdaq Capital Market. The trading on NYSE American will end on March 3, 2025, with Nasdaq trading commencing on March 4, 2025, under the same ticker symbol ‘IBIO.’ The company believes this move will enhance visibility, trading liquidity, and exposure to institutional investors, aligning with its strategy to join a community of leading biotech firms.